(PEPG) PepGen Inc. BCG Matrix Research

PepGen Inc.’s Stars were still only early stage at the end of 2025: the lead PGN-EDO51 and follow-on PGN-EDO45 programs were in Phase 1/2, while the rest of the pipeline stayed preclinical. That means the portfolio had scientific upside, but no approved product, no revenue base, and no market leadership yet.

In BCG terms, these assets can become Stars only if clinical data prove clear benefit and the Company can convert that into a launch. Until then, the pipeline is better viewed as a high-risk option on future growth, not a current leader.

• Two clinical-stage programs, still unproven
• Preclinical assets add optionality, not leadership

PepGen Inc., founded in 2018 and headquartered in Cambridge, is still a young biotech, so it has not had time to build a broad, high-share commercial base. That is why the Stars quadrant stays empty in a BCG Matrix view.

With no mature, scaled product platform yet, PepGen’s focus remains on pipeline progress, not on defending large market share. In biotech, that often means R&D spend leads sales for years before a star asset can emerge.

• 2018 founded
• Cambridge HQ
• Young biotech
• Empty Stars quadrant

PepGen Inc. is not a cash cow; it is a pre-commercial biotech that funds R and D with capital markets, not product sales. That means operating cash is driven by equity or debt financing, which is typical before commercialization and the opposite of a mature, self-funding business.

In BCG terms, this is a cash drain, not a cash generator, because R and D spend comes before any meaningful product income. The key test is simple: if cash burn is financed externally, the model depends on investor capital, not internal cash flow.

PepGen Inc. showed no evidence of surplus operating cash from sales in FY2025, so it could not self-fund expansion from operations. With no product revenue and no dividends, the Cash Cows quadrant does not apply.

• No surplus operating cash
• No self-funded expansion
• No cash cow fit

Its cash use depended on external funding, not product cash flow.

PepGen Inc. had 0 commercial products in FY2025, so its disclosed pipeline was not in a low-growth cash-cow lane. With no marketed revenue and all key programs still in clinical development, the portfolio fit uncertainty-driven question marks, not Dogs under BCG.

• 0 approved, revenue-bearing programs
• All candidates still in development
• No mature low-growth cash cows

This matters because Dogs need weak growth and weak market share in an established business, and PepGen Inc. had neither in 2025.

PepGen Inc.’s dog quadrant stayed empty because there was no marketed product to trap cash in a declining brand. In FY2025, spend was still centered on R&D burn and pipeline work, not legacy product upkeep, so there was no cash-draining brand to classify as a Dog.

• No marketed product.
• R&D burn, not brand maintenance.
• Dog quadrant stayed empty.

PepGen Inc.'s PGN-EDO45 extends its Duchenne muscular dystrophy pipeline into exon 45, adding another development asset but no approved-product revenue yet. That keeps it a low-share, high-upside Question Mark in the BCG Matrix, with value tied to clinical readouts and capital access rather than current sales.

• Exon 45 expands the DMD reach
• No approved-product status yet
• High potential, low market share
• Clinical data will drive value

PGN-EDO44 is an earlier-stage Duchenne muscular dystrophy (DMD) exon-skipping program, so it fits PepGen Inc.'s "Question Mark" bucket: high medical need, but no commercial revenue yet. DMD affects about 1 in 3,500 to 5,000 male births, but exon 44 skip-amenable patients are only a small slice of that pool.

• Early-stage, no sales yet
• Medically important niche
• Unclear future conversion
• Needs clinical proof